Pre launch · Nutraceuticals · GB

Rejuvion Sciences

Raising £1M
$18.7M
Revenue
74%
Gross Profit Margin
$1.4T
Annual economic cost of obesity
$47T
Estimated cost of chronic diseases globally
The problem
Obesity continues to rise as a global health epidemic, setting off a chain reaction of chronic conditions such as diabetes, liver disease, and certain cancers. Inflammation is emerging as a hidden driver of morbidity, escalating healthcare crises and contributing to the burden of chronic diseases.
Our solution
Rejuvion Sciences is developing scientifically-backed plant extracts to address obesity and inflammation without the side effects of pharmaceutical alternatives. The company leverages ethnobotanical knowledge and scientific validation to create effective nutraceuticals.
Product

What we've built and what's next.

  1. 01
    Supports satiety with plant extracts underpinned by ethnobotanical knowledge from Kew Gardens
  2. 02
    Reduces blood glucose, insulin requirements, and glycemic index through clinically supported ingredients
  3. 03
    Uses Capsimax and Innoslim to enhance fat metabolism and fat breakdown
  4. 04
    Formulation inhibits pro-inflammatory mechanisms and supports anti-inflammatory activity
Market

A category big enough to build a company inside.

Total Addressable
$500B
global · The whole category opportunity.
30% category CAGR
Target segments
  • 01
    Broader market20–70 years old · unisex
  • 02
    Primarily older adults40–70 years old · interested in longevity, inflammaging, chronic disease management
Geography
Global
$500B
Why now

The market is moving — timing matters.

The rising global health epidemic of obesity and the emerging role of inflammation as a hidden driver of morbidity create a pressing need for effective solutions. The market is shifting towards natural and plant-based ingredients, with a significant portion of consumers preferring these options for healthcare products.

  • 01
    78% global consumers prefer natural and plant-based ingredients in healthcare products
  • 02
    High exponential rise of world’s herbal medicine market
Traction

The numbers, said plainly.

Revenue
$18.7M
Year 1
Gross Profit Margin
74%
Year 1
Annual economic cost of obesity
$1.4T
global
Estimated cost of chronic diseases globally
$47T
2030
US adults starting GLP-1 therapy
174,000
2019 to 2023
GLP-1 prescriptions in EU
4.2M
2018 to 2023
Gross margin
74%

Formulations underway for initial launch in UK, followed by the US and Western European expansion.

Unit economics

What it costs to make a dollar.

74%
Gross margin
Competition

Where we sit.

Positioning
Us Competitors
High · Depth of capability
Low
Low
Customer outcome · High
Us · Rejuvion Sciences
VITABIOTICS
GNUTRILITE
HERBALIFE
Rejuvion Sciences
Our edge

Built to win in this category.

VITABIOTICS

Market size of $44B, known for consumer-centric approach and institutional credibility.

GNUTRILITE

Market size of $26B, focuses on scientific excellence and market advantages.

HERBALIFE
Defensibility

What protects this advantage.

Regulatory & compliance
Licences
EU Food Supplements Directive 2002/46/EC — Establishes harmonized lists of vitamins and minerals permitted in food supplements, along with specific labeling requirements (such as recommended daily doses and warnings not to exceed them).
Team

Built by people who've shipped this before.

Adam Kelliher
Adam Kelliher
CEO

25+ years in Life Sciences, taking companies from inception to high value. Founded, built and sold Equazen Ltd (to Galenica) and Equateq Ltd (to BASF). CEO of NASDAQ-listed Avita Medical plc (regenerative medicine). PE/VC adviser

Equazen LtdEquateq LtdAvita Medical plc
Henry Chamberlain
Henry Chamberlain
CFO
LH
Lee Harle
Co-Founder
Advisors
Prof Monique Simmonds OBE
Deputy Director of Science at Kew Gardens
30 years' experience of research into different aspects of plant and fungal chemistry with an emphasis on the economic value of natural products
Prof Clare Bryant FBPhS
Professor of Innate Immunity at University of Cambridge
A Fellow of the American Academy of Microbiology. Expertise in inflammation, infection and anti-inflammatory pharmacology
Giles Yeo
Professor of Molecular Neuroendocrinology at the University of Cambridge
Programme leader at the MRC Metabolic Diseases Unit. Expertise in genetics of obesity, appetite regulation, and science communication
In their own words
“
Rejuvion Sciences is a cutting-edge nutraceutical company developing scientifically-backed plant extracts to address the twin global crises of obesity and inflammation without the side effects and limitations of pharmaceutical alternatives.
EXECUTIVE SUMMARY
“
Our innovation is fuelled by our academic alliances and unmatched scientific resources.
SCIENTIFIC FOUNDATION
“
A solution targeting satiety, fat metabolism, and glucose regulation.
PRODUCT PIPELINE
The ask

What we're raising — and what it builds.

Raising

£1M

Use of funds
Development£30k for development
—
Website & Digital Assets£35k to establish a strong digital and visual presence
—
Product Development£25k to finalise product development
—
Key Talent£50k to order product inventory and validate propositions
—
Regulatory & Compliance
—
Comparable rounds & valuations
The Good Bug2025
₹100 crore (approx. $12 million) Series B
Fullife Healthcare2026
₹300 crore (approx. $32 million) Series D
What this round buys
  • — D2C launch of Satimax and Inflamesse products in Q4 ’25
  • — Scale in the UK and US market entry
Get in touch
Data room

Request access to these files.

The financial model, cap table, references and the rest of the diligence pack — granted by the founder, one click for signed-in investors.

The pitch

Read it the way they pitched it.

Rejuvion Sciences
Powered by craise.ai